Peptide Graded

Lutetium Lu-177 vipivotide tetraxetan

Is Lutetium Lu-177 vipivotide tetraxetan legal in the US?

Yes, FDA approved for advanced prostate cancer that has spread and carries a marker called PSMA.

AStrong human evidenceFDA approvedas of 2026-10-26

Approved. Lutetium Lu-177 vipivotide tetraxetan (Pluvicto, Novartis) was approved in March 2022 for PSMA-positive metastatic castration-resistant prostate cancer after androgen receptor pathway inhibition and taxane chemotherapy, extended in March 2025 to patients who have not had chemotherapy, and extended again in mid-2026 to PSMA-positive metastatic hormone-sensitive prostate cancer in combination with an androgen receptor pathway inhibitor and androgen deprivation therapy. 23

Read the full Lutetium Lu-177 vipivotide tetraxetan page

More on Lutetium Lu-177 vipivotide tetraxetan

Citations

  1. Sartor 2021, NEJM: Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer (VISION) doi.org
  2. Novartis: Pluvicto US prescribing information novartis.com
  3. FDA 2026: Pluvicto prescribing information, expanded indication accessdata.fda.gov

Reference information only, not medical advice. Drawn from the Lutetium Lu-177 vipivotide tetraxetan article, fact-checked against the cited sources. No dosing anywhere on this site.